ERBB2 mutation: A promising target in non-squamous cervical cancer.
ERBB2 mutation: A promising target in non-squamous cervical cancer.
复制标题
ERBB2 突变：非鳞状宫颈癌的一个有希望的靶点。
DOI：
10.1016/j.ygyno.2017.12.023
复制
发表时间：
2018
影响因子：
4.7
通讯作者：
Yang Huijuan
中科院分区：
文献类型：
--
作者：
Xiang Libing;Jiang Wei;Ye Shuang;He Tiancong;Pei Xuan;Li Jiajia;Chan David Wai;Ngan Hextan Yuen Sheung;Li Fang;Tao Pingping;Shen Xuxia;Zhou Xiaoyan;Wu Xiaohua;Yang Gong;Yang Huijuan
在浸润性宫颈癌（ICC）的一个子集中发现了ERBB 2突变。然而，患病率，突变谱，临床病理相关性，人乳头瘤病毒（HPV）基因型相关性和预后意义的ERBB 2突变ICCs尚未建立良好methodsIn这项研究中，ICC样本（N= 1015）进行了评估ERBB 2，KRAS，PIK 3CA的突变，基于cDNA的桑格sequencing. Resultsomatic ERBB 2突变检测3.15%的患者。ERBB 2基因突变率在腺癌（4.52%，7/155）、腺鳞癌（7.59%，6/79）和神经内分泌癌（10.34%，3/29）中均显著高于鳞癌（2.14%，16/749）（P= 0.004，Fisher精确检验）。此外，18.75%携带ERBB 2突变的患者同时携带PIK 3CA或KRAS突变。ERBB 2突变的ICCs患者往往有一个更坏的预后比野生型或PIK 3CA突变的ICCs，但比那些KRAS突变的ICCs.ConclusionsThis研究提供了一个有前途的理由酪氨酸激酶抑制剂的临床研究，用于治疗宫颈癌ERBB 2突变。非鳞状细胞癌患者优先作为ERBB 2靶向治疗的候选者。在临床试验设计中应考虑并发PIK 3CA/RAS突变。
ObjectiveERBB2 mutations have been found in a subset of invasive cervical cancer (ICC). Nevertheless, the prevalence, mutation spectrum, clinicopathological relevance, human papillomavirus (HPV)-genotype association and prognostic significance of ERBB2-mutated ICCs have not been well established.MethodsIn this study, ICC samples (N= 1015) were assessed for mutations in ERBB2, KRAS, and PIK3CA by cDNA-based Sanger sequencing.ResultsSomatic ERBB2 mutations were detected in 3.15% patients. The ERBB2 mutation rate was significantly higher in adenocarcinoma (4.52%, 7/155), adenosquamous carcinoma (7.59%, 6/79) and neuroendocrine carcinoma (10.34%, 3/29) than that in squamous carcinoma (2.14%, 16/749) (P= 0.004, Fisher exact test). In addition, 18.75% of the patients carrying ERBB2 mutations concomitantly harbored PIK3CA or KRAS mutations. Patients with ERBB2-mutated ICCs tended to have a worse prognosis than those with wild-type or PIK3CA-mutated ICCs but a better prognosis than those with KRAS-mutated ICCs.ConclusionsThis study provided a promising rationale for the clinical investigation of tyrosine kinase inhibitors for the treatment of cervical cancer with ERBB2 mutations. Patients with non-squamous cell carcinomas have priority as candidates for ERBB2-targeted therapy. Concurrent PIK3CA/RAS mutations should be considered in the design of clinical trials.
登录
查看更多内容
影响因子：
7.3
作者：
Gao J;Aksoy BA;Dogrusoz U;Dresdner G;Gross B;Sumer SO;Sun Y;Jacobsen A;Sinha R;Larsson E;Cerami E;Sander C;Schultz N
通讯作者：
Schultz N
HER2插入YVMA突变肺癌：悠久的自然史和对阿法替尼的反应。
DOI：
10.1016/j.lungcan.2015.10.025
发表时间：
2015-12
期刊：
Lung cancer (Amsterdam, Netherlands)
影响因子：
--
作者：
Li BT;Lee A;O'Toole S;Cooper W;Yu B;Chaft JE;Arcila ME;Kris MG;Pavlakis N
通讯作者：
Pavlakis N
影响因子：
64.8
作者：
通讯作者：
--
DOI：
10.1056/nejmoa1309748
发表时间：
2014-02-20
期刊：
The New England journal of medicine
影响因子：
--
作者：
Tewari KS;Sill MW;Long HJ 3rd;Penson RT;Huang H;Ramondetta LM;Landrum LM;Oaknin A;Reid TJ;Leitao MM;Michael HE;Monk BJ
通讯作者：
Monk BJ
影响因子：
--
作者：
Xiang L;Li J;Jiang W;Shen X;Yang W;Wu X;Yang H
通讯作者：
Yang H